Trans Genic Group reports FY2025 loss amid restructuring

Trans Genic Group (TSE:2342) announced its consolidated financial results for the fiscal year ending March 2025, reporting a net loss attributable to owners of the parent of JPY 1,089 million, a significant downturn compared to the profit of JPY 4 million in the previous year. Operating loss totaled JPY 259 million, versus a JPY 89 million profit last year. Revenues decreased slightly to JPY 13,005 million, down from JPY 13,083 million in FY2024. The drug discovery support business saw a revenue decline of 18.2% due to project delays, while the investment and consulting segment improved by 3.2%. The company forecasts revenues of JPY 13,500 million and a net profit of JPY 40 million for FY2026.